C ongenital heart disease (CHD) is the most common type of birth defect, with a reported prevalence ranging from 6 to 13 per 1000 live births. 1, 2 In the United Kingdom alone, there are %4600 babies born with CHD each year. Despite a constant decline in mortality rate, CHD still represents the primary cause of death among infants in industrialized countries. The definitive therapeutic option for these patients is corrective surgery. 3 However, prostheses currently used to reconstruct complex cardiac defects, including synthetic Gore-tex material, xenografts and homografts, are unable to match the growth of an infant's heart and they become dysfunctional over time. 4 Consequently, CHD patients usually undergo repeated risky, distressing, and costly operations for replacement of failed grafts. The cost of reoperation on a healthcare budget is substantial. In the United States, the direct healthcare expenditure for every 100 cases undergoing cardiac reoperation is over $2.4 million. Cell therapy and tissue engineering hold promises for the repair of injuries to, or congenital defects of complex organs including the heart. 5, 6 The underlying concept is that incorporation of cells shall confer prosthetic grafts with the characteristics of a living tissue that grows and remodels in a physiologic manner in parallel with cardiac and whole-body growth. 7, 8 Initial preclinical and clinical studies focused on the implantation of valve leaflets seeded with vein-derived autologous endothelial cells (ECs), 9 or peripheral bloodderived endothelial progenitor cells. 10, 11 However, for complex cardiac defects, such as tetralogy of Fallot, which require both valve replacement and ventricular reconstruction, a spectrum of cells able to reconstitute all the components of the heart should be considered. Multipotent stem cells (SCs) offer the all-in-one solution, whereas lineage-committed progenitor cells represent a safer option.
Pericytes are attracting attention for use in regenerative medicine and tissue engineering approaches. 12 In the heart, pericytes act as an interface between the coronary vasculature and cardiomyocyte compartment, playing an important role in maintenance of cardiac homeostasis and repair. 13 Whether pericytes represent a homogeneous population remains a matter of debate. A recent study reported that immunosorted CD146 pos /CD34 neg perivascular cells from fetal and adult myocardium share certain phenotypic and developmental similarities with skeletal muscle pericytes, yet exhibit different antigenic, myogenic, and angiogenic properties, thus suggesting the heterogeneity of pericytes derived from diverse anatomical locations. 14 Additionally, a different pericyte subtype expressing the transmembrane glycoproteins CD34 and CD105 together with stemness markers, but negative for CD146 as well as vasculogenic (a-smooth-muscle actin), hematopoietic (CD45), and endothelial (CD31) markers, has been described by us and others in the adventitia of large vessels. [15] [16] [17] [18] Our group was the first to identify that the adventitia of human fetal aorta contains CD34 pos progenitor cells capable of inducing vasculogenesis, angiogenesis, and myogenesis 15 and starting from this discovery has then moved to appreciate the presence of CD34 pos pericyte progenitors in adult saphenous vein leftover material from coronary artery bypass graft surgery. 16 Importantly, we have shown that, in models of peripheral and myocardial ischemia, transplantation of adventitial pericytes stimulates tissue repair both directly, acting as vascular progenitor cells, and indirectly, promoting the formation/maturation of new vessels, attracting pro-angiogenic monocytes and resident cardiac SCs (CSCs) and inhibiting cardiac fibrosis. 15, 16, 19 Comparing fetal and adult pericytes, we have also appreciated the higher plasticity of those derived from the youngest donors. 15, 16 This prompted us to hypothesize that leftover material from pediatric cardiac surgery might represent a rich source of cells to be applied in regenerative medicine approaches. Since this has not been studied so far, we have embarked on this program of research. Hence, the present study aimed to verify whether cells similar to adventitial pericytes exist in human hearts. Using a standard operating procedure previously set up to obtain pericytes from surplus of human veins, we have been able to isolate and expand millions of pericytes from small cardiac leftovers obtained during CHD surgery. We found that these cardiac pericytes (CPs) are able to differentiate into vascular smooth muscle cells (VSMCs), attract ECs and CSCs, produce extracellular matrix proteins, and colonize a decellularized xenograft routinely used in cardiac surgery. Pericytes expanded from small leftovers of palliative surgery may represent a new therapeutic cell product for tissue engineering-based correction of CHD.
Methods Ethics
Clinical characteristics of patients recruited to the study are shown in Table. Studies complied with the principles stated in the Declaration of Helsinki. The protocol for collection of cardiac leftovers from patients undergoing corrective surgery of CHD was approved by the North Somerset and South Bristol Research Ethics Committee (REC reference 11/SW/0122). The protocol for collection of saphenous veins samples was approved by Bath Research Ethics Committee (REC reference 06/Q2001/197). Adult patients and pediatric patients' custodians gave written informed consent for inclusion in the study. We have applied a good manufacturing practices-compliant standard operating procedure previously employed for derivation of pericytes from human saphenous vein. 16 CPs were isolated from atrium or ventricle specimens (3 to 5 mm, <100 mg) from infants and children undergoing surgical repair for congenital heart defects. In brief, discarded tissue was thoroughly washed in PBS and then manually minced. The tissue suspension was incubated for 40 minutes with 0.45 WU/mL/g Liberase 2 (Roche Technologies, UK). Passing the cell suspension sequentially through 70, 40, and 30-lm cell strainers ensured single cell suspension. Cells were depleted for ECs with anti-CD31 conjugated beads (Miltenyi Biotech, UK), following the manufacturer's instructions. The remaining cells were purified by selecting CD34+ cells by anti-CD34 beads (Miltenyi Biotech). Target cells were cultured in the presence of EGM2 medium (Lonza, UK) supplemented with 2% fetal bovine serum (FBS). Adherent colonies were passaged to new culture dishes once they reached 60% to 70% confluence and frozen stocks were generated after Passage 2 for the experiments shown in this study. Trypsin-EDTA (Life Technologies, UK) was utilized to detach cells from the growth substrate.
Flow Cytometry Analysis
CPs were stained for surface antigen expression using combinations of the following antibodies to confirm typical phenotype at P5: anti-CD31 (eBioscience, UK), anti-CD34 (eBioscience), anti-CD44 (eBioscience, UK), anti-CD45 (Miltenyi Biotec), anti-CD90 (BD Biosciences, UK), anti-CD105 (Life Technologies), and anti-CD146 (Miltenyi Biotec). After staining, fluorescence was analyzed using a FACS Canto II flow cytometer and FACS Diva software (both BD Biosciences, UK). 
Immunofluorescence Analysis

CPs Growth Curve
Three CP lines were cultured in the microvascular medium EGM-2+2%FBS and 2 mesenchymal stromal cell media (STEM-MACS+10%FBS from Miltenyi Biotec, and DMEM+20%FBS from Life Technologies) to determine the optimal expansion medium for the cells. CPs (30 000) were seeded in each well of a 6-MW plate at day 1, and cells were detached and counted at day 4, 5, 6, 7, and 8 of culture.
Clonogenic Assay
To test the ability of CPs to generate colonies starting from a single cell, CPs (n=4) at P5 were selected as Propidium
Iodide negative (live cells) and sorted into single cells using a BD Bioscience Influx sorter (BD Biosciences, UK). Sorted cells were placed into each well of a 96-well culture plate (Greiner Bio-one, UK). The sorted cells were cultured up to 4 weeks in EGM-2 and the number of colonies generated was counted.
Multilineage Differentiation Toward the 3 Cardiovascular Lineages
The ability of CPs to differentiate into cardiomyocytes, ECs or VSMCs were tested following exposure to inductive media as previously described. 16, 20, 21 Cells were seeded at 5000 cells/ cm 2 and allowed to become confluent. The culture media exchange every 3 days, for 14 to 21 days. The following differentiation methods and media were used: (1) Endothelial cell differentiation: ECs were generated using either a previously described method-which provides the culture of cells in medium enriched with 10 ng/mL human VEGF (vascular endothelial growth factor, PeproTech EC Ltd, UK) -or CFU-Hill Liquid Medium Kit (StemCell Technologies, UK).
(2) Cardiomyocyte cell differentiation: 2 different previously published methods were employed. The first is based on the culture of cells with a medium containing ascorbic acid (Sigma-Aldrich), 10 ng/mL human basic fibroblast growth factor, 10 ng/mL human VEGF, and 10 ng/mL human insulinlike growth factor 1 (all from PeproTech EC Ltd). The second method described in Smits et al, consists of an initial 3 daylong incubation of the cells with 5 lmol/L 5-aza-2 0 -deoxycytidine (Sigma-Aldrich) followed by the culture of cells with a medium containing ascorbic acid and 1 ng/mL human transforming growth factor b-1 (PeproTech EC Ltd). (3) Vascular smooth muscle cell differentiation: differentiation medium added with 20 ng/mL of human PDGF-BB (PeproTech). All the experiments were performed in triplicate with 2 to 4 cell lines assessed.
Analysis of CPs Cell Secretome by ELISA
The quantities of the following secreted proteins were determined in CPs cultured when cells were exposed to normoxic conditions for 48 hours in serum-free medium: human VEGF, basic fibroblast growth factor, hepatocyte growth factor, angiopoietin-1, angiopoietin-2, and stromal cells-derived factor 1, transforming growth factor-b1, and procollagen type I (all from R&D Systems, UK). ELISAs were performed following manufacturer's instructions. Cytokine concentrations were expressed normalizing the data for the number of the cells at the end of the collection time, and for the time of incubation. Four different CPs lines were assessed and experiments were performed in triplicate.
In Vitro Matrigel Assay
Network formation was performed as described previously. 16 Briefly, CPs were labeled with VyBrant diI (Life Technologies) and seeded with human umbilical vein endothelial cells (HUVECs, Lonza, UK, 1:4 ratio of CPs to HUVECs, respectively) in a 96-well plate at 7000 cells/well on top of 70 lL thick-coated Matrigel (BD Biosciences) in EGM2 with FBS for 6 hours. HUVECs and CPs were also seeded alone as a control. To assess the effect of CP-secretome, CP-conditioned media diluted 1:2 with fresh EGM-2 and FBS were incubated with 7000 HUVECs/well on top of 70 lL thickcoated Matrigel for 6 hours. HUVECs with un-conditioned EGM-2 were also seeded alone as a control. FBS concentration was the same in all the experimental conditions. CPsalone network formations were also assessed at different cell numbers (2000, 5000, 7000). Images were taken under bright-field at 59 and the length of the networks was measured. All experiments were performed in triplicate with 3 to 4 cell lines assessed.
Labeling of Cells With DiI Tracker
For selected in vitro experiments, CPs were stained with the long-term cell trackers VyBrant diI (Life Technologies). DiI was diluted 1:1000 in PBS and incubated with confluent cells (adherent to the culture plate) for 5 minutes at 37°C and then on ice for an additional 15 minutes, in the dark. Cells were then washed with PBS, left to recover for 24 hours, and used for experiments.
Transwell Migration Assay
To test the capacity of CPs secretome to induce the migration of human CSC and HUVECs, 60 000 CSC or HUVECs were seeded in 24-well plates on a 6.5-mm Transwell â with 5.0-lm pore polycarbonate membrane insert (Corning, UK), in serum-free EGM-2 medium (Lonza).
In the bottom of the wells, 0.5 mL of CPs serum-free conditioned medium was added. Serum-free EGM-2 medium was used as negative control. Serum-free EGM-2 supplemented with human VEGFa (100 ng/mL; PeproTech EC Ltd) was used as a positive control for HUVECs. Cells were incubated for 16 hours at 37°C. At the end of this period, the membrane inserts were washed with PBS, fixed with icecold methanol for 15 minutes at room temperature, stained with DAPI, and mounted on a slide. Membranes were analyzed with an epifluorescence microscope at 9200 magnification; 10 fields were randomly acquired and cells counted. Migrated cells were expressed as a percentage. Experiments were performed in duplicate. Four different CPs lines were assessed. . Protocols were generated and data recorded using pClamp 10 software (Axon Instruments) via an A/D converter (Digidata 1440A, Axon Instruments/Molecular Devices, USA). Whole-cell membrane currents were recorded in voltage-clamp mode using either a ramp protocol, in which membrane potential was ramped from À120 mV to +80 mV over 400 ms from a holding potential of either À40 mV or À80 mV, or a step protocol, in which membrane potential was stepped between À120 mV and +80 mV in increments of 10 mV for 500 ms, from a holding potential of either À40 mV or À80 mV. Ramps and steps were applied at a frequency of 0.2 Hz. Data were filtered at 1 kHz and digitized at 10 kHz.
Measurement of Membrane Current and
To measure intracellular Ca 2+ , CPs were incubated with 5 lmol/L Fluo-4/AM (Life Technologies) for 25 minutes at room temperature, before being rinsed in control solution. The cells were then placed in an experimental chamber mounted on the stage of either a Fluoview 1200 (Olympus, Germany) or Pascal (Zeiss, Germany) inverted confocal microscope, and superfused with control solution at room temperature. Fluo-4 fluorescence was stimulated at 488 nm. Fluorescence was normalized to F/F 0 as described previously, following correction for photobleaching. 22 Cells were stimulated either electrically, via parallel Pt wires connected to an SD8 Grass Stimulator, or using 10 lmol/L BT 3 -IP 3 /AM (a membranepermeable form of IP 3 ) or 10 mmol/L caffeine added to the superfusate.
Assays on Gene Expression
RNA isolation and quantitative real time (RT) polymerase chain reaction (PCR)
Extracted total RNA was reverse-transcribed into singlestranded cDNA using a High Capacity RNA-to-cDNA Kit (Life Technologies) or using specific primers provided with the Taqman miRNA assay and microRNA Reverse Transcription Kit (Life Technologies 
Static Culture of Cardiac Pericytes on the CorMatrix
Sunnyvale, CA) -a decellularized xenograft material clinically approved for use in cardiac surgery -of %1.5-cm diameter were cut and placed in wells of a 24-well plate.
To fix the bioscaffold pieces to the bottom of the wells, CellCrown inserts were used (Sigma-Aldrich). Prior to the seeding, the bioscaffolds were incubated for 2 days with EGM-2 media. CPs (50 000) at P5 were seeded into each CorMatrix-containing well and maintained for 7 days on the bioscaffolds. The bioscaffolds were fixed in 4% Paraformaldehyde for 20 hours at 4°C and imbedded in paraffin or OCT-frozen. Eight-micrometer sections were examined for the presence of CPs using anti-vimentin, NG2, and PDGFR-b antibodies (see above), which were incubated for 20 hours at 4°C after permeabilization and blocking. Secondary antibody was incubated on the sections for 1 hour at room temperature. The nuclei were counterstained with DAPI (Sigma-Aldrich). The slides were mounted using Fluoromount-G â mounting media (Sigma-Aldrich) and immunofluorescence pictures were taken after 24 hours both at 920 and 940.
seeded CorMatrix was grown in an InBreath Bioreactor (Harvard Apparatus, Holliston, MA). The device ensures maintenance of sterility and stabilization, automation, and scale-up/-out of the cellularization process through hydrodynamic stimuli and control of nutrients and oxygen transport to the cells. The conduit was stitched to the rotating arm of the Bioreactor and stitched back onto itself so as to fashion a tube shape through the center of which runs the rotating arm.
The Bioreactor was filled with EGM-2 medium and placed into the incubator at 37°C with the medium being changed twice a week. At the end of the total 3 weeks of culture, the viability of the seeded cells on the scaffolds was detected using the Biotium fluorescent viability/cytotoxicity Assay kit. Fluorescence imaging was carried out on the whole thickness of graft. Tissue-engineered scaffolds were then analyzed by histological staining of the nuclei and of the extracellular matrix components elastin and collagen, detected, respectively, by hematoxylin and eosin (H&E) and Elastic Van Gieson staining.
Statistical Analysis
GraphPad Prism was used to perform the statistical analysis. Due to the limited number of samples (n=3 to 4, too small), a normality test could not be performed. For this reason, 2-group analysis was performed by nonparametric MannWhitney test. Values were expressed as meansAEstandard error of the mean (SEM). Probability values (P) <0.05 were considered significant.
Results
Immunohistochemical Localization of CPs
Multiple staining immunohistochemistry and confocal microscopy were used for cell localization in cardiac tissue ( 
Isolation/Expansion and Characterization of CPs
The good manufacturing practices-compliant standard operating procedure, previously employed for derivation of saphenous vein pericytes, 16 proved to be highly efficient when applied to cardiac leftovers, with an expansion success (%20 million cells at P5, in 4 to 6 weeks) of 10 samples out of 13 examined. This is a remarkable result, considering the weight of source cardiac tissue in comparison with saphenous veins ( Figure S1 ). CPs can be successfully expanded in EGM-2 supplemented with 2% FBS (both from Lonza), a microvascular media that we already use for optimal expansion of saphenous vein pericytes. The attempt to culture CPs in 2 mesenchymal stromal cell media (STEM-MACS+10%FBS from Miltenyi Biotec, and DMEM+20%FBS from Life Technologies) clearly showed that EGM-2 is the optimal medium for expansion of CPs ( Figure S2 ). With use of contrast phase microscopy, expanded cells show typical spindle-shape morphology (Figure 2A Figure 2B ). In contrast, there was a scarcity/absence of endothelial-CD31 and hematopoietic-CD45 markers. Another unique characteristic is the lack of CD146, which distinguishes the isolated population from CD146 pos pericytes described previously in postmortem samples from fetal and adult hearts. 14 Moreover, as shown by us with saphenous vein-derived pericytes, expansion in culture was associated with an expected downregulation of CD34. Immunocytochemical analyses showed the consistent expression of vimentin (100%), NG2 (95%), and PDGFRb (58%). Additionally, expanded cells were positive for the cardiac transcription factor GATA-4 (47%) and for the stemness markers OCT-4 (64%), SOX-2 (54%), and NANOG (34%) ( Figure 3A ). Around 30% of the total population showed coexpression of OCT4/NANOG and SOX-2/NANOG ( Figure 3B ). The expression of stemness markers slightly decreased along with cell expansion, from passage 3 to passage 5 of culture (OCT-4 58%, SOX-2 50%, NANOG 28%), but the difference was not significant (MannWhitney test, OCT-4 P=0.72, SOX-2 P=0.23, NANOG P=0.63) ( Figure 3C ). As expected, a further decreasing trend was observed up to passage 9 (OCT-4 39% and NANOG 14%, Mann-Whitney test P3 versus P9: OCT-4 P=0.4, NANOG P=0.1). Finally, CPs did not express the mast/stem cell growth factor receptor (SCFR/c-Kit), indicating their distinction from classical cardiac stem cells currently used in clinical trials 23,24. We next assessed the ability of CPs (n=4 donors) to secrete growth factors, cytokines, and extracellular matrix protein (Figure 4) . We found that hepatocyte growth factor was the most abundant secreted factor, followed by angiopoietin 2, VEGF-A, angiopoietin 1, stromal cell derived factor-1a, and fibroblast growth factor-B. Furthermore, we found that CPs release procollagen type 1, a major constituent of cardiac extracellular matrix, in conditioned media (0.8AE0.1 ng/mL, n=4 lines). Instead, CPs do not release transforming growth factor-b1 in the culture media.
Comparison with saphenous vein-derived pericytes indicates similarity of the 2 cell populations, though CPs are more abundant in NG2 and express a spectrum of SC-associated antigens ( Figure S3A ). Moreover, CPs secrete more hepatocyte growth factor (6-fold), angiopoietin 2 (8-fold), FGF (4-fold), and VEGF (6-fold) than saphenous vein-derived pericytes ( Figure S3B ).
Clonogenic and Differentiation Potential
To investigate whether CPs are able to form clones, we seeded them (P5, from 4 donors) into 96-well Terasaki plates (1 cell per well). One week after sorting, we observed the formation of first colonies that contained 5 to 20 cells. At 4 weeks, we found that CPs from atrium or ventricle give rise to similar numbers of clones (10% and 11% of seeded cells, respectively), a result that surpasses the reported clonogenic activity of saphenous vein-derived pericytes (7%). 16 We next exposed CPs (n=4 donors) to differentiation stimuli for derivation of vascular and cardiac lineages. As shown in Figure 5A , CPs do not express typical VSMC antigens. Following exposure to a differentiation medium enriched with human platelet-derived growth factor BB (PDGFBB), 25 they initially acquired the expression of nonmuscle myosin B, which is typical of synthetic VSMCs, and then additionally expressed retinol-binding protein 1, a-smoothmuscle actin, and smooth muscle-calponin, suggesting their maturation into a contractile phenotype. The analysis of gene expression by quantitative real time-PCR ( Figure 5B ) confirmed a marked induction of a-smooth-muscle actin (average 18-fold increase after 14 days) and SM-calponin (157-fold), while typical antigens of mature contractile VSMCs were less upregulated (smooth muscle-myosin heavy chain, average 5.5-fold increase after 14 days, and smoothelin, 4.2-fold increase). In addition, retinol-binding protein 1 mRNA levels peaked at 7 days (3.1-fold) and returned to basal level at 14 days. Culture of CPs in CFU-Hill Medium or a medium enriched with human VEGF-A failed to induce the expression of mature endothelial proteins as detected by immunocytochemistry (KDR/VEGFR2, von Willebrand Factor, VE-Cadherin) (data not shown); quantitative PCR analysis confirmed only a slight increase of von Willebrand Factor (2.5-fold), while CD31 and KDR were not increased or even downregulated (5-fold decrease), respectively, after the differentiation protocol compared to baseline CPs ( Figure 5B) .
To induce the differentiation into cardiomyocytes, we adopted 2 protocols that differ from each other in terms of growth factor composition and presence or absence of the epigenetic modifier 5-Azacytidine. 20, 21 We observed that CPs acquire the expression of a-Sarc-actinin and connexin-43, but do not show the localized pattern typically seen in mature cardiomyocytes ( Figure 5C ). Furthermore, quantitative real time-PCR analyses ( Figure 5B ) confirmed the induction of connexin-43 (average 9-fold increase after 21 days), T-box transcription factor (Tbx5, a marker of cardiac development, 1.5-fold), and calcium channel, voltage-dependent, L type, a1C subunit (CNAC1C, average 18-fold). However, the mesoderm marker brachyury, early cardiac markers Islet-1, and NK2 homeobox 5 (NKX2.5) as well as myosin heavy chain 7, cardiac muscle, b (MYH7) could not be detected. Failure of CPs to acquire typical cardiac transcription factors may indicate the incapacity to transverse the whole differentiation process.
To further verify the cardiomyogenic potential of CPs, we next assessed their electrical properties before and after induction of differentiation. Figure 6 shows examples of membrane current ( Figure 6A) release from intracellular stores via ryanodine receptors, had no effect on intracellular Ca 2+ (n=5 out of 5 cells). As a positive control, 110 mmol/L CaCl 2 was added to the perfusate, which resulted in an increase in intracellular Ca 2+ in 3 out of 4 cells (insert in lower right panel of Figure 6B ).
Interaction of CPs With ECs and CSCs
Recruitment of cardiac cells into the graft is important for its functionalization. CPs may help this process by releasing chemoattractant factors. In line with this possibility, results illustrated in Figure 7A and 7B indicate that the conditioned medium of CPs exerts strong attractive actions on c-kit pos CSCs and ECs in an in vitro migration assay (8-fold increase in CSC and 15-fold increase in ECs migration as compared to unconditioned media; both n=4 donors, Mann-Whitney test, P<0.03). In addition, CPs are able to form networks in Matrigel in a dose-related fashion ( Figure S4 ) and to enhance the network forming activity of ECs depending on the direct contact between the 2 cell types (2-fold; n=3, Mann-Whitney, P<0.05) ( Figure 7C and 7D ). These data confirm our previous findings of cooperative interactions between adventitial pericytes and ECs instrumental to promotion of vascular growth and stabilization. 16 Instead, the proangiogenic effect was not observed when ECs were incubated with CPconditioned media ( Figure 7E ). However, cautiousness is necessary when excluding a paracrine action of CPs in the observed phenomena, as direct contacts are often necessary to deliver chemical signals between cells. Furthermore, we have recently shown that cells in coculture influence the paracrine activity of each other. 26 
Successful Seeding in Clinical-Grade Grafts
Finally, we seeded CPs (50910 3 or 50910 4 cells/cm 2 ) on CorMatrix, a clinically approved xenograft material, and cultured them for 1 week under static conditions. In additional experiments, at the end of the 1-week static culture, the pericyte-engineered graft was transferred to a double-chamber rotating bioreactor, for an additional 2 weeks. Successful cellularization of the graft texture was demonstrated with histological stainings for cell nuclei and cytoplasm (hematox- (Figure 9 ). Cell viability within the engineered scaffold was confirmed with live-cells imaging using the Biotium viability/cytotoxicity Assay kit ( Figure 10 ).
Discussion
Clinical cell therapy for heart disease has been aimed at promoting the healing of ischemic myocardium in adult patients. New evidence suggests that SC therapy could potentially offer a new treatment standard for patients with CHD. 27 Importantly, the neonatal heart offers a wider and more na€ ıve spectrum of cellular options than the adult heart.
The field is still in its beginning, with initial clinical studies showing evidence of feasibility and safety. 28 Here, we show new data on progenitor cells that could be considered for tissue engineering in patients with CHD. Using a standard operating procedure previously set up to obtain pericytes from human saphenous veins, we have now isolated, expanded, and characterized a novel population of CPs from both atria and ventricle of infants and children with CHD.
The idea of "recycling" and expanding regenerative cells from tiny surplus material of palliative surgery suggests a sustainable therapeutic undertaking. The reported expansion success (%20 million cells at P5, in 4 to 6 weeks in 77% of samples examined) largely surpasses the outcome previously obtained with saphenous vein leftovers. 16 This may be due to either a greater abundance or higher proliferation rate of founder cells from the neonatal heart as compared with counterpart cells from the adult vasculature. however, as stated by Chen et al, the possibility of fusion of pericytes with feeder cells cannot be excluded. Moreover, given that Chen and colleagues worked on cardiac biopsies that were obtained postmortem from subjects that had died from noncardiac causes, we cannot exclude the possibility that differences in cell behavior could be associated with the heart conditions and/or with the standard operating procedure. While we processed our samples immediately after harvesting, it is conceivable the necrosis in samples might have been present for a longer time before reaching the tissue culture laboratory and the undefined causes of death might have affected the epigenetic and molecular signature in Chen's samples. Although unable to differentiate in ECs and cardiomyocytes, CPs possess other reconstitutive properties that make them relevant for tissue repair and engineering. We show that CPs exert chemoattractive activity toward ECs and form tubular networks in Matrigel alone and in a cooperative fashion with ECs. They also produce large amounts of growth factors and cytokines implicated in angiogenesis. Additionally, CP conditioned media remarkably stimulate the recruitment of human CSCs. CPs also release procollagen type 1, a major constituent of cardiac extracellular matrix. Finally, in view of creating a pericyte-engineered graft for correction of congenital heart defects, we seeded CPs in a xenograft scaffold under static and dynamic conditions. Engineering of prosthetic grafts with autologous SCs has the 2-fold aim of reducing the thrombogenic risk through reendothelialization of the graft's luminal surface and conferring the properties of a living tissue that grows and remodels in a physiologic manner in parallel with cardiac and whole body growth. Results show that CPs are able to penetrate deeply within the graft texture after 3 weeks of culture in a bioreactor system, and that cells within the graft are viable. Moreover, cells maintain the original antigenic phenotype.
With respect to other competing/complementary solutions for cellularization of cardiac grafts, CPs appear to be a more refined and safer cell therapy product. For instance, CPs can be isolated/expanded from the tiny discarded tissue (<100 mg) obtained at palliative CHD surgery, whereas the scarcity of other SCs in the heart precludes this possibility. Moreover, pericytes do not induce calcification when implanted in the heart of mice, as observed with mesenchymal SCs. 19 CPs may be preferred to pericytes from other organs, because the former do not require an elective harvesting procedure and are assumed to engraft more efficiently in their native tissue. A recent clinical trial showed the feasibility, safety, and therapeutic efficacy of intracoronary administration of autologous cardiosphere-derived cells in children with hypoplastic left heart syndrome. 28 Comparison of CPs and cardiosphere-derived cells indicates some similarities, as both cell populations express CD105, CD90, vimentin, and GATA4 and are negative for CD31 and CD45. However, different from cardiosphere-derived cells, CPs do not express Tbx5, NKX2.5, and FLK1. Furthermore, cardiosphere-derived cells classically express c-Kit, 24 which is instead absent in CPs. Therefore, the 2 cell types may represent distinct and potentially complementary therapeutic elements within the pool of cardiac SCs.
In conclusion, we provide a method to isolate and expand a unique population of pericytes from surgery remnants of congenitally defective hearts. This is of high clinical relevance because the starting material is usually available during palliative surgery without additional risk or burden to the patient. The method allows easy preparation and expansion of the cells to provide elements that accomplish important requirements for cell therapy and tissue engineering, being expandable in vitro and able to produce essential extracellular protein and angiogenic factors, stimulate angiogenesis, attract CSCs, and engraft into biodegradable prosthetic material with high efficiency. Pericyte-engineered grafts could be prepared using a good manufacturing practices-compliant protocol at the time of the first operation in patients born with tetralogy of Fallot or the more severe variant of pulmonary atresia (usually a palliative procedure such as a shunt) using a small amount of tissue collected from the right atrium. The tissue-engineered grafts will then be ready for implantation within the 3-to 4-month gap that normally separates the palliative operation at birth with the final complete surgical correction. Although a long multistep procedure is required to test the good manufacturing practices quality of a cellular product in order to reach clinical applicability, including preclinical in vivo studies in animal models of CHD, with this first study we aimed at demonstrating the feasibility of isolating and expanding several million of CPs from tiny myocardial samples of the youngest patients, and their properties that may elect CPs as good candidates for use in reconstructive surgery. Currently, the scarce availability of commercial animal models of complex CHD limits the possibility of testing the in vivo regenerative ability of CPs, but our surgical team is working in this direction. Indeed, our next step will be represented by feasibility studies with CPs in an animal model of CHD. This approach may open new avenues for correction of complex congenital cardiac defects with immense medical and social benefits.
